Related Experiment Video

Updated: Jun 16, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Recent advancement in developing small molecular inhibitors targeting key kinase pathways against triple-negative

Rajibul Islam1, Khor Poh Yen2, Nur Najihah 'Izzati Mat Rani2

  • 1School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia.

Bioorganic & Medicinal Chemistry
|August 19, 2024
PubMed

Insights

Triple-negative breast cancer (TNBC) is aggressive, lacking targeted therapies. Protein kinase inhibitors show promise as potent treatments for this lethal breast cancer subtype.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) is the most aggressive subtype, disproportionately affecting younger women.
  • TNBC presents a poor prognosis and high metastatic potential due to the lack of targeted therapies.
  • Protein kinases are critical in TNBC progression and drug resistance, representing viable therapeutic targets.

Purpose of the Study:

  • To review the efficacy of small molecule kinase inhibitors in treating triple-negative breast cancer.
  • To highlight the potential of combination therapies involving kinase inhibitors for TNBC.
  • To explore future directions for novel therapeutic development against TNBC.

Main Methods:

  • Literature review of preclinical and clinical studies on small molecule kinase inhibitors in TNBC.
  • Analysis of studies investigating combination therapies for TNBC.
  • Synthesis of current research on targeting protein kinases in TNBC.

Main Results:

  • Small molecule kinase inhibitors demonstrate significant potential in combating TNBC.
  • Combination strategies involving kinase inhibitors show synergistic effects against TNBC.
  • Targeting specific kinases offers a promising avenue for novel TNBC therapies.

Conclusions:

  • Small molecule kinase inhibitors are effective in treating the most lethal form of breast cancer.
  • Further research into kinase inhibition pathways can lead to improved TNBC treatments.
  • Targeted therapies offer a hopeful future for patients with triple-negative breast cancer.
Keywords:
ApoptosisClinical trialsKinasesMetastasisSynergisticTNBC

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K